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Innsbruck, and Linz, Austria, and Cambridge, United KingdomBackground: The search for intrinsic factors, which account for
a protein’s capability to act as an allergen, is ongoing. Fold
stability has been identified as a molecular feature that affects
processing and presentation, thereby influencing an antigen’s
immunologic properties.
Objective: We assessed how changes in fold stability modulate
the immunogenicity and sensitization capacity of the major
birch pollen allergen Bet v 1.
Methods: By exploiting an exhaustive virtual mutation screening,
we generated mutants of the prototype allergen Bet v 1 with
enhanced thermal and chemical stability and rigidity. Structural
changeswere analyzed bymeans of x-ray crystallography, nuclear
magnetic resonance, and molecular dynamics simulations.
Stability was monitored by using differential scanning
calorimetry, circular dichroism, and Fourier transform infrared
spectroscopy. Endolysosomal degradation was simulated in vitro
by using the microsomal fraction of JAWS II cells, followed by
liquid chromatography coupled to mass spectrometry.
Immunologic properties were characterized in vitro by using a
human T-cell line specific for the immunodominant epitope of Bet
v 1 and in vivo in an adjuvant-free BALB/c mouse model.
Results: Fold stabilization of Bet v 1 was pH dependent and
resulted in resistance to endosomal degradation at a pH of 5 or
greater, affecting presentation of the immunodominant T-cell
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http://dx.doi.org/10.1016/j.jaci.2015.09.026allergy-promoting TH2-type immune response. Efficient TH2
cell activation required both an increased stability at the pH of
the early endosome and efficient degradation at lower pH in the
late endosomal/lysosomal compartment.
Conclusions: Our data indicate that differential pH-dependent
fold stability along endosomal maturation is an essential
protein-inherent determinant of allergenicity. (J Allergy Clin
Immunol 2016;137:1525-34.)
Key words: Allergic sensitization, Bet v 1, structural stability, endo-
lysosomal degradation, antigen processing and presentation, molec-
ular allergology
Among the plethora of environmental antigens towhich human
subjects are regularly exposed, only a few display a high
propensity to act as allergens triggering type I allergic diseases
(ie, TH2-biased immune responses characterized by aberrant
levels of IgE production). Allergens encompass a diverse group
of molecules that address innate immune pathways through
protease activity, lipid binding, engagement of pattern recognition
receptors, molecular mimicry of Toll-like receptor signaling
molecules, or provision of complex carbohydrate structures.1
Interestingly, allergens can be found in only 2% of all known
protein families, and the distribution of allergens is highly biased
toward a few of these protein families.2 Hence it is obvious to
speculate that beyond the abovementioned particular intrinsic bio-
logical functions, common structural and biochemical determi-
nants of allergenicity might exist that have yet to be determined.
Bet v 1.0101 (Bet v 1), the major allergen found in birch pollen,
belongs to family 10 of the plant pathogenesis-related proteins
and is the most intensely studied allergen. Its structure,3 as well as
its T- and B-cell epitopes,4-7 are known. The hydrophobic cavity
of Bet v 1 has been demonstrated to bind a variety of ligands,8
including pollen-derived quercetin,9 an iron-binding catechol
derivative. Recently, the apo-form of Bet v 1 (loaded with
catechol in the absence of iron) has been suggested to have a
TH2-promoting potential.
10 Moreover, binding of the model
ligand deoxycholate has been implicated in compaction and
rigidification of the Bet v 1 molecule11 and stabilization of its
conformational epitopes.12 These data indicate that the structural
stability of Bet v 1 represents a determinant of its allergenicity.
To investigate solely the effect of conformational stability on
the sensitization capacity of Bet v 1, we used an approach lacking
any immunologically relevant confounders, such as artificial
ligands or immunization with adjuvants. We generated variants of1525
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light scatteringBet v 1 with enhanced fold stability by means of introducing 1, 2,
3, or 4 sequential point mutations. Mutations were selected based
on a recently developed in silico approach that uses normalized
knowledge-based energy potentials for predicting the influence
of single point mutations or combinations thereof on protein
stability.13 In-depth comparison of the Bet v 1 mutants with the
wild-type protein revealed increased thermal and chemical
stability, reduced backbone flexibility, and enhanced resistance
to degradation by proteases. In the absence of adjuvants, the
wild-type molecule induced only marginal immune responses,
whereas the stabilized mutants triggered significant serum IgG
and IgE titers and IL-4 production. Allergenicity and immunoge-
nicity of the mutant proteins strongly correlated with protease
resistance at slightly acidic pH and efficient proteolytic
processing at lower pH, resembling the early and late endosomal
environment, respectively. Based on our findings, we propose that
differential, pH-dependent fold stability in the early versus late
endosomal compartment is a protein-inherent key determinant
of allergenicity.
METHODS
Expression and purification of recombinant
proteins
Wild-type Bet v 1 and the 4 mutants were expressed from pET28b
constructs in Escherichia coli strain BL21 Star (DE3; Invitrogen, Carlsbad,
Calif), as described in the Methods section in this article’s Online Repository
at www.jacionline.org.
Protein characterization and structure
determination
Protein folding in solution and thermal and chemical denaturation were
monitored by using differential scanning calorimetry (DSC), circular
dichroism (CD), and Fourier transform infrared spectroscopy (FTIR). The
monomeric state was measured by using size exclusion chromatography
coupled tomultiangle light scattering (SEC-MALS). Structurewas determined
by means of x-ray crystallography. Protein flexibility was assessed by
using molecular dynamics simulations, nuclear magnetic resonance (NMR)
spectroscopy, and hydrogen/deuterium exchange. These methods are
described in detail in the Methods section in this article’s Online Repository.Mice and immunizations
Female 6- to 10-week-old BALB/c mice were obtained from Charles River
Laboratories (Sulzfeld, Germany) and maintained at the animal facility of the
University of Salzburg according to local guidelines for animal care. Animal
experiments were approved by the Austrian Ministry of Science (permit no.
BMWFW-66.012/0008-WF/II/3b/2014).Mice (n5 5)were immunized 5 times
with 20 mg of Bet v 1 or one of the mutant proteins in sterile PBS by means of
intradermal injection into the ear pinnae on days 0, 14, 28, 42, and 81. A total
volume of 80mLwas divided between the 2 sides. Blood samples were taken at
regular intervals. Mice were killed on day 88 for preparation of splenocytes.Antibodies and cytokines
Levels of IgG1 and IgG2a subclass antibodies in sera measured on day 88
were evaluated by using a luminometric ELISA14 at serum dilutions of
1:300 and 1:100, respectively, lying within the linear range of the assay.
The IgE cross-linking capacity of the mutant proteins was assessed by
using ab-hexosaminidase release assay, as described in theMethods section in
this article’s Online Repository.
The amount of cell-bound IgE was measured by using a basophil activation
test, as previously described.15 Heparinized whole blood taken on day 84 of
the experimental schedule was diluted 1:2 with RPMI 1640 and incubated
with 10 ng/mL Bet v 1 or the respective mutant or left untreated as a control
for 2 hours at 378C and 5% CO2. Cells were washed, and surface staining was
performed with anti-CD200 R (clone OX110; eBioscience, San Diego, Calif),
anti-IgE (clone RME-1; BioLegend, San Diego, Calif), anti-CD4 (clone
GK1.5, BioLegend), and anti-CD19 (clone 6D5, BioLegend). Subsequently,
cells were washed with PBS/1% BSA/2 mmol/L EDTA and analyzed on a
FACSCanto II flow cytometer (BD Biosciences, San Jose, Calif).
Splenocytes from immunized mice were prepared and cultured, as
previously described,14 in the presence of Bet v 1 or the mutants
(20 mg/mL) to determine the number of IL-4 and IFN-g producers per
2 3 105 cells by using ELISpot (Millipore, Bedford, Mass).Endolysosomal degradation simulations
Endolysosomal degradation assayswereperformed, as previously described.16
Briefly, 5mg of protein substrates (Bet v 1 andBet_mut1 toBet_mut4)wasmixed
with 8mgof isolatedmicrosomal fraction from the JAWSII cell line in 50mmol/L
citrate buffer (pH 5.9, pH 5.2, or pH 4.5) and 2 mmol/L dithiothreitol.
The pool of peptides generated from Bet v 1 and the mutants in the
degradation assay at pH 5.2 and pH 4.5 was assessed by using mass
spectrometry with a Q-Exactive Orbitrap Mass Spectrometer (Thermo Fisher
Scientific, Waltham, Mass) with nanoelectrospray and nano-HPLC (Dionex
Ultimate 3000, Thermo Fisher Scientific). For details, see theMethods section
in this article’s Online Repository.Uptake and processing of Bet v 1 and Bet variants
by monocyte-derived dendritic cells and
stimulation of Bet v 1–specific T cells
Experiments involving human cells were conducted in accordancewith the
guidelines of the World Medical Association’s Declaration of Helsinki.
Samples of human origin were obtained from blood donations, and use of
residual cells was approved by the Institutional Review Board of Upper
Austria. Monocyte-derived dendritic cells (moDCs) were generated from
buffy coats from healthy anonymous donors (provided by the Red Cross
Transfusion Service of Upper Austria), as described in the Methods section in
this article’s Online Repository. For investigating the uptake kinetics of Bet v 1
and its variants, moDCs were incubated with DyLight488-labeled proteins at
20 mg/mL for 30, 60, and 120 minutes, respectively, and uptake was
determined by means of flow cytometry.
moDCs from HLA-DRB1*07:01–restricted donors were incubated for 30 to
480minuteswithBetv 1 or themutants at 20mg/mL.Subsequently,moDCswere
washed and cocultured with Jurkat T cells expressing a Bet v 1142-153–
specific T-cell receptor and harboring a human IL-2 promoter/enhancer control-
ling luciferase expression17 for 6 hours. Cells were lysed in 50mL of lysis buffer
(100 mmol/L potassium phosphate, 0.1% Triton X-100, and 1 mmol/L
dithiothreitol), and luciferase activity was measured in a Tecan Infinite 200 Pro
microplate reader with 50 mL of luciferase substrate (Promega, Madison, Wis).RESULTS
Generation of Bet v 1 mutants with increased fold
stability
We have previously demonstrated the use of knowledge-
based potentials for generating destabilized allergens.13
TABLE I. Bet v 1 mutants used in the study
Protein Mutations Combined z score
Bet v 1 — 28.34
Bet_mut1 D69I 28.9
Bet_mut2 D69I, K97I 29.34
Bet_mut3 D69I, K97I, P90L 29.80
Bet_mut4 D69I, K97I, P90L, G26L 210.18
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structure relations in known 3-dimensional protein structures,
describing the interactions between amino acid residues and the
interaction of the residues with the surrounding solvent. By using
this method, a z score is generated, which indicates either
stabilization (decrease of z score) or destabilization (increase of
z score).18 Here we applied this approach to generate fold-
stabilized mutants of Bet v 1. By using in silico permutation of
every amino acid, mutants were selected, which predicted the
strongest stabilizing effect. The immunodominant region of Bet
v 1 (Bet142-156)
4 was excluded from the mutation process to avoid
changes in immunogenicity because of destruction of T-cell
epitopes. Likewise, solvent-exposed residues (accessible surface
area >30%), which can contribute to IgE binding,19 were left
untouched. In an iterative manner, up to 4 point mutations were
introduced, resulting in the generation of Bet_mut1, Bet_mut2,
Bet_mut3, and Bet_mut4 (Table I). All selected mutations were
located in regions representing minor T-cell epitopes recognized
by only 3.5% to 8.8% of allergic donors4 or 0% to 3.3% of
sensitized BALB/c mice,20 respectively.
Proteins were expressed tag-free in E coli and purified by using
hydrophobic interaction chromatography and anion exchange
chromatography, followed by an endotoxin removal step. The
final purity was greater than 99%, as determined by using SDS-
PAGE (see Fig E1, A, in this article’s Online Repository at
www.jacionline.org), and preparations were essentially LPS
free (<0.4 pg/mg protein). Identity was confirmed by means of
mass spectroscopy (see Fig E1, B), and the correct conformation
(see Fig E1, C) and monomeric state (see Fig E1, D) of the
proteins were demonstrated by using CD spectroscopy and
SEC-MALS, respectively.
A more detailed analysis with x-ray crystallography showed
that the 3-dimensional structures of the mutants were remarkably
similar to that of thewild-type protein. The superimposition of the
crystal structures of the quadruple mutant Bet_mut4 with Bet v 1
revealed that the overall fold is identical, with a total root-mean-
square deviation of 0.7 A (Fig 1).
Overall fold identity was also confirmed by using an IgE-
binding assay with rat basophil leukemia (RBL) cell degranula-
tion (see Fig E2, A, in this article’s Online Repository at www.
jacionline.org), which demonstrated that all mutants had retained
the capacity to cross-link cell-bound IgE. This indicates that
surface epitopes were mainly left intact by the introduction of
stabilizing mutations. Degranulation was slightly lower in the
mutants compared with the wild-type protein, suggesting the pos-
sibility of subtle changes to conformational epitopes. Likewise,
an RBL assay and a basophil activation test were performed
with human sera from donors with birch pollen allergy. All mutant
proteins showed very similar IgE-binding capacity compared
with the wild-type Bet v 1 (see Fig E2, B and C). This confirmsthat the surface structure of the recombinant mutant proteins
resembles that of naturally occurring Bet v 1.
Introduction of the point mutations effectively enhanced the
thermal and chemical fold stability of Bet v 1, as assessed by using
CD spectroscopy and DSC. All proteins were analyzed in
phosphate buffer at pH 7.4. The first mutation (D69I) was sufficient
to enhance chemical stability (ie, the amount of urea required to
induce 50% unfolding of the protein) from 2.8 to 5.2 mol/L urea,
corresponding to a shift in Gibbs-free energy (DG) of approxi-
mately 4 to 5 kcal/mol (Fig 2, A). Interestingly, the additional mu-
tations showed no additive effect. This was confirmed by results of
thermal denaturation analysis in which D69I induced a shift of
greater than 208C in melting temperature (Fig 2, B-D). Inclusion
of the P90L mutation in mutants 3 and 4 led to evident aggregation
at temperatures of greater than 808C, as indicated by the distorted
baseline after the transition peak (marking the transition from
native to unfolded state) in the DSC diagram (Fig 2, C). Despite
this complexity, the same pattern of stabilization for these mutants
over wild-type protein was observed at different protein concentra-
tions (0.15-0.5mg/mL; Fig 2,C). In the case ofmutant 4, therewas
also an additional reproducible decrease in baseline before the
transition peak of unknown origin. A similar stabilization for the
mutants of approximately 5 kcal/mol could be estimated from
the DSC data. Thermal denaturation was not repeatable, indicating
a nonequilibrium mechanism and thus preventing detailed
interpretation of the DSC data. However, the data indicated the
exact same pattern and magnitude of significant fold stabilization
seen in chemical and thermal denaturation by using CD (Fig 2, A
and B).Increased fold stability enhances allergenicity and
immunogenicity
BALB/c mice were immunized intradermally into the ear
pinnae with the respective protein dissolved in PBS to assess
immune response in the absence of immunomodulatory
confounders, such as adjuvants. As shown in Fig 3, A, Bet v 1
was nonimmunogenic in this adjuvant-free setting. In contrast,
mutants 2, 3, and 4 induced significantly higher titers of Bet v
1–specific IgG1 and low levels of IgG2a. Notably, antibody
responses against the homologous mutant protein in the
individual groups (with few exceptions) closely resembled those
observed against the wild-type protein, underscoring the high
degree of conformational homology of the mutant proteins (see
Fig E3 in this article’s Online Repository at www.jacionline.
org). Introducing fold-stabilizing mutations not only increased
the immunogenicity in terms of IgG1 production but also resulted
in the formation of allergen-specific IgE, which was mainly cell
bound (Fig 3, B). This was most prominent for mutant 4, which
also induced high levels of IL-4–secreting splenocytes (Fig 3,
C) and detectable levels of free, allergen-specific serum IgE
(Fig 3, B). No significant levels of IFN-g were detected in any
group (Fig 3, C). In summary, allergenicity and immunogenicity
were increased with every additional introduction of a fold-
stabilizing mutation, with the most striking effects observed for
the mutant harboring 4 point mutations.Fold-stabilizing mutations reduce flexibility
The data shown above clearly point to an effect of the
number of fold-stabilizing mutations on allergenicity and
FIG 1. Crystal structure of the quadruple mutant Bet_mut4 (blue) in comparison with Bet v 1 (gray, PDB:
4A88). Superimposition of Bet_mut4 with Bet v 1 revealed that the overall fold is conserved. A, Mutated
residues D69I, K97I, P90L, and G26L are shown as sticks. B, An enlarged view of the mutated residue
D69I shows that it is stabilized by several hydrophobic residues, including Ile56, Phe58, Val67, Tyr83, and
Val85. C, The surface-exposed mutation K97I is likely to entropically stabilize the protein by releasing
coordinated solvent molecules. D, Mutation P90L induced an alternative conformation, as indicated.
E, Mutation G26L fills a hydrophobic cavity formed by Phe21, Ile22, and Phe30. All mutated residues are
shown as blue sticks compared with sticks from wild-type Bet v 1 (gray). The electron density map
(2Fobs-Fcalc) is contoured at 1 s over the mean.
FIG 2. Thermal stability of Bet v 1 and mutant proteins 1 to 4 (Bet_mut1-4). A, Chemical denaturation was
assessed bymeans of CD spectroscopy, and the fraction of denatured protein (Fdenatured) is displayed. B and
C, Thermal denaturation was measured by using CD (Fig 2, B) and DSC (Fig 2, C). DSC data for wild-type Bet
v 1 andmutants were run at a 608/h scan rate and at 0.15 mg/mL (lower traces) and 0.5 mg/mL (upper traces)
offset in the y-axis for clarity. D, Melting points calculated from DSC data.
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FIG 3. Influence of fold-stabilizingmutations on the immunogenicity and sensitization capacity of Bet v 1. A,
Bet v 1–specific IgG1 and IgG2a titers of BALB/c mice (n 5 5) immunized intradermally with the different
proteins were measured by using a luminometric ELISA at a serum dilution of 1:300 for IgG1 and 1:100
for IgG2a. Data are shown as relative light units (RLU). B, Bet v 1–specific IgE levels in serumwere measured
with an RBL degranulation assay, and results are presented as the percentage of total release. Cell-bound
IgE was assessed by using a basophil activation test, and data are shown as stimulation indices (SI).
C, Numbers of IL-4– and IFN-g–secreting splenocytes after restimulation with Bet v 1 and the respective
mutants were determined by using the ELISpot assay. SFU, Spot-forming units. Statistical significance
compared with Bet v 1 was assessed by using 1-way ANOVA, followed by the Dunnett post hoc test.
*P < .05, **P < .01, and ***P < .001.
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thermal stability. Because the flexibility of a protein is known to
influence the accessibility of lysosomal proteases and hence
presentation of peptides on MHC molecules,21,22 we studied the
molecular dynamics of the wild-type molecule and the 4 mutants
with simulations over 100 ns for each system by using
AMBER12.23 To capture residue-wise flexibility, we calculated
B factors for Ca atoms from the resulting conformational
ensembles of the proteins after global alignment. Furthermore,
we calculated dihedral entropies based on the distributions of
torsion angles of the protein backbone.24 Simulation data indicate
that all systems are rigidified considerably by the introduction of
the point mutations. Local dynamics of residues around the
mutation sites are especially reduced, thus pointing to a gain in
stability (see Fig E4 in this article’s Online Repository at www.
jacionline.org).
To experimentally confirm changes in flexibility, we used
hydrogen/deuterium exchange measurement with FTIR. Asshown in Fig 4, A, all mutants showed an overall slower exchange
rate compared with the wild-type protein, indicating reduced
molecular dynamics. However, at this much slower time scale,
Bet_mut4 turned out to be themost rigidmolecule. These findings
could be further substantiated by using relaxation dispersion
NMR,25 which confirmed the substantial decrease in flexibility
on the microsecond-to-millisecond time scale in Bet_mut4
(Fig 4, D) compared with Bet_mut1 (Fig 4, C) and the wild-
type molecule (Fig 4, B).Protease-mediated degradation is reduced in fold-
stabilized mutants
To assess whether the increased thermal stability and reduced
flexibility of fold-stabilized mutants indeed affects the degrada-
tion of the protein in the endolysosome, we performed a
degradation assay using microsomal enzyme preparations of
JAWS II cells at different pH values, thus simulating the pH
FIG 4. A-D, Influence of fold-stabilizing mutations on the molecular flexibility of the protein, as indicated by
hydrogen deuterium exchange (Fig 4, A) and relaxation dispersion NMR (Fig 4, B-D). In Fig 4, B-D, the 11
residues with the largest backbone amide 15N relaxation dispersion profiles are displayed.
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endolysosome.
The degradation assay revealed no detectable proteolysis of Bet
v 1 at pH 5.9, which might reflect an intrinsic stability of wild-
type Bet v 1, as well as a reduced proteolytic activity at this pH,
but a complete degradation at a pH of 5.2 within 12 hours, as
assessed by using SDS-PAGE (Fig 5, A). In contrast, all mutants
were resistant to proteolysis under these conditions. However, at
lower pH, Bet_mut4 suddenly became susceptible to degradation.
Interestingly, this change in protease susceptibility at lower pH
correlated with a reduced thermal stability, as assessed by using
CD spectroscopy (monitoring protein unfolding; Fig 5, B) and
FTIR (here used for monitoring aggregation by unfolding; Fig
5, C). Analysis of the resulting peptides with liquid chromatog-
raphy coupled to mass spectrometry revealed that processing of
Bet v 1 progresses from the N- and C-termini of the molecule
to the inner core. Proteolysis of the mutants followed a similar
pattern, although at lower speed (Fig 5, D). No differences in
the population of generated peptides were observed between
Bet v 1 and its variants, indicating that no cleavage sites were
introduced or removed by the inserted point mutations (full degra-
dation patterns at different pH can be found in Figs E5-E14 in thisarticle’s Online Repository at www.jacionline.org). It must be
taken into account that these degradation processes will happen
much faster in vivo because of the extremely high local
concentration of proteolytic enzymes in the endolysosome. For
example, cathepsin concentrations in lysosomes can well exceed
1 mmol/L,26 which is at least 106-fold higher compared with the
concentrations used in our in vitro assays. Nevertheless, the assay
qualitatively resembles the course of in vivo processing because
the full proteolytic machinery is present in the endolysosomal
preparations.16Presentation of the immunodominant epitope
Bet142-153 is enhanced in Bet_mut4
Uptake of Bet v 1 and the mutant proteins by moDCs was
monitored by pulsing cells with DyLight488-labeled proteins.
Flow cytometric analysis revealed no differences with regard to
the percentage of antigen-positive cells (Fig 6, A) and their mean
fluorescence intensity (Fig 6, B).
To rule out that the increase in immunogenicity observed for
Bet_mut2-4 might be due to the generation of new T-cell epitopes
by the mutation process, we investigated the activation of a
FIG 5. A-D, Proteolytic degradation of Bet v 1 and the mutants Bet_mut1 to Bet_mut4 (Fig 5, A and D) and
their thermal stability (Fig 5, B and C) at different pH values. Proteolytic degradation was assessed by using
15%SDS-PAGE and Coomassie staining (Fig 5,A). Thermal stability was followed by using CD spectroscopy
(Fig 5, B), and thermally induced aggregation was followed by using attenuated total reflectance FTIR (Fig 5,
C). FTIR data are presented as the fraction of aggregated protein versus temperature. Protein degradation
patterns over time were analyzed by using liquid chromatography–mass spectroscopy (Fig 5, D): peptides
generated earlier during the proteolytic processing are colored in white, whereas peptides that were not
detected during the whole experiment (48 hours) were colored in black. Amino acid positions are labeled
at the top. The immunodominant epitope of Bet v 1 is framed in green.
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FIG 6. A and B, In vitro antigen processing and presentation. Uptake of
DyLight488-labeled Bet v 1 and Bet_mut1-4 by moDCs. The percentage of
positive cells (Fig 6, A) and their mean fluorescence intensity (MFI; Fig 6,
B) were analyzed by using flow cytometry. moDCs from HLA-
DRB1*07:011 donors were preincubated with Bet v 1 or Bet_mut1-4 for
the indicated time span and subsequently cocultured with Bet142-153–
specific Jurkat T cells. C, Luciferase reporter expression under control of
the IL-2 promoter was measured after 6 hours of coculture. Data are shown
as means 6 SEMs of relative light units (RLU) of 2 independent
experiments by using 2 different donors.
FIG 7. Model for immunogenicity/allergenicity of an allergen depending on
differential fold stability at different endosomal pH. During antigen uptake
and processing, allergens face a broad range of different pH values, ranging
from approximately 7.4 in the extracellular matrix to approximately 4.0 in
the terminal lysosome. Proteins with low fold stability in the early
endosome are proteolytically processed prematurely, resulting in poor
antigen presentation because of low abundance of MHC class II in this
compartment (‘‘blue’’ protein). Proteins with high fold stability at low pH
(‘‘black’’ protein) remain structurally intact until they reach the terminal
lysosome, where againMHC class II levels are low and antigen presentation
is inefficient. Only proteins that survive the early endosome but are
efficiently processed at a more acidic pH can accumulate in the late
endosome, where they are finally degraded and loaded on highly abundant
MHC II molecules (‘‘red’’ protein).
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specific for the immunodominant peptide Bet142-153. moDCs
from a HLA-DRB1*07:01–positive donor were cultured with
Bet v 1 and the mutant proteins for 30 to 1440 minutes before
adding Jurkat cells expressing the specific T-cell receptor. Six
hours later, T-cell activation was determined by measuring a
luciferase reporter under control of the IL-2 promoter.17
Although antigen uptake was similar for the wild-type protein
and the 4 mutants, Bet_mut4 (and, to a lesser degree, Bet_mut3)
showed enhanced T-cell stimulatory capacity, especially at the
early time points (Fig 6, C). This indicates that larger amounts of
the immunodominant peptide are presented by moDCs when
processing the fold-stabilized mutants Bet_mut3 and Bet_mut4.
Notably, both variants were highly stable at a pH of greaterthan 5.2 while becoming destabilized at lower pH. These
in vitro data from human cells remarkably resemble in vivo data
from mouse experiments (Fig 3), supporting a mechanism for
immunogenicity being dependent on high stability in the early
endosome and protease susceptibility in the late endosome.DISCUSSION
Recent concepts link protein-intrinsic features, such as
protease activity, molecular mimicry, and ligand binding, to
allergic immune responses.1,27 However, there are very few data
dealing with the role of protein fold stability concerning induction
of a TH2 immune response.
28
Antigen processing and presentation consists of several steps,
including uptake/internalization of proteins, reduction of
disulfide bonds and unfolding, endosomal/lysosomal proteolysis,
and loading of peptides onto MHC class II molecules. Because
proteases preferentially degrade proteins in a denatured state,
unfolding represents an indispensable step for intracellular
processing of protein antigens.29 Interestingly, modifying
proteins to increase their stability has produced contradictory
results. Some studies reported decreased T-cell or antibody
responses when immunizing with stabilized antigens,30-32
whereas others could correlate increased stability/slower
proteolytic degradation of internalized antigens with prolonged
retention of antigen in secondary lymphoid organs and enhanced
presentation of T-cell epitopes33 and increased humoral and
long-lasting cellular immunity.34-36 Reduced susceptibility to
degradation might not only enhance the preservation of CD41
T-cell epitopes but also prolong the persistence of the proteins
for sustained processing and presentation by DCs and even allow
for transfer of intact antigen to B cells.37,38
In the present study we used an unbiased computational
approach and generated Bet v 1 mutants with a striking increase
J ALLERGY CLIN IMMUNOL
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the wild-type molecule. The stabilizing effects of the mutations
D69I, K97I, and G26L can be explained by the local environment
within the crystal structure (Fig 1, A). Contrasting the original
Asp69, the isoleucine matches the hydrophobic nature of the
cavity formed by Ile56, Phe58, Val67, Tyr83, and Val85.
Additionally, several solvent molecules were released in the
mutated structure compared with the wild-type structure, leading
to an entropically driven stabilization (Fig 1, B). A similar effect
was also observed for K97I, which is located on the protein
surface. Furthermore, the conformation of the neighboring
residue Glu95 was slightly different, thus stabilizing the
hydrophobic residue with its aliphatic chain (Fig 1, C). The
mutation P90L induced an alternative conformation in the main
chain of the surrounding residues as indicated, which is more
difficult to interpret with respect to its effect on stability (Fig 1,
D). Mutation G26L fills an internal hydrophobic cavity formed
by Phe21, Ile22, and Phe30 (Fig 1, E).
Taken together, all the introduced mutations were aliphatic
residues oriented toward the hydrophobic cavity of Bet v 1 (Fig
1). These mutations act like anchors responsible for the dramatic
rigidification of the molecular structure predicted by molecular
dynamics (see Fig E4) and further confirmed by hydrogen/deute-
rium exchange and NMR (Fig 4). Interestingly, binding of model
ligands to the hydrophobic cavity of Bet v 1 has been shown to
result in rigidification11 and reduced proteolytic degradation12
of the protein, which is similar to what we observed in our
experimental system. Ligand binding to Bet v 1 has also been
linked to its allergenic potential.10,12 However, in our ligand-
free system we could demonstrate for the first time that not the
ligand itself but the change of the structural stability of the protein
represents the underlying general principle of immunomodula-
tion. Also, we can exclude aggregation39 as a biologically
relevant mechanism for the observed effects because aggregation
events only took place at temperatures of greater than 608C
(Fig 2, C).
In a recent publication Ohkuri et al31 have suggested that a
certain energy threshold exists that solely defines whether a
protein is immunogenic. Our data clearly indicate that this is an
oversimplification not reflecting the complex effect of
pH-dependent protein stability in the course of degradation, start-
ing in the early and moving to the late endosomal compartment. It
has to be taken into account that antigens face a continuous
decrease in pH from 7.4 (in the extracellular environment) to
4.0 in terminal lysosomes. Indeed, we could demonstrate that
the mutant proteins Bet_mut1 to Bet_mut4 show similarly high
stability at neutral pH; however, they strongly differ in their
stability and proteolytic susceptibility at acidic pH, and this
affects their immunogenicity. Interestingly, the dominant T-cell
epitope of Bet v 1 was found to be highly susceptible to degrada-
tion independent of pH or time point in in vitro degradation assays
(Fig 5, D, and see Figs E5-E14); indeed, we never identified the
full-length peptide Bet142-153. This suggests that in vivo this
epitope has to be protected from proteolytic degradation, possibly
by binding to class II molecules.40
On the basis of these results, we propose a model (Fig 7) in
which immunogenicity/allergenicity is determined by a
pH-dependent balance of protease accessibility of allergens,
resulting in optimal loading of MHC class II. It is known that
the early endosome (approximately pH 6) and the terminal
lysosome (approximately pH 4.0-4.5) are poor in MHC class II,whereas late endosomes (approximately pH 4.5-5.5) display
high quantities of MHC class II organized in multivesicular
bodies.41 The poor immunogenicity of Bet v 1 after vaccinating
mice in the absence of adjuvant can be explained by the low
proteolytic stability of the molecule along the endosome
maturation, a process highly conserved between species.42,43
This results in low peptide abundance in the late endosome, in
which the majority of MHC loading takes place.41 Interestingly,
a similarly low immunogenicity can be observed for Bet_mut1,
although it is extremely stable to pH-mediated unfolding. The
resulting poor accessibility to proteases leads to the same effect
as low proteolytic stability (ie, low peptide abundance in
the late endosome and suboptimal MHC loading). In contrast,
Bet_mut4 is highly stable at a pH of greater than 5, suggesting
that it accumulates during the early endosomal maturation and
can then be processed efficiently in the late endosome, where it
becomes susceptible to degradation. Our in vivo mouse data are
further substantiated by in vitro data from human moDCs (Fig
6). Thus the differential stability of Bet_mut4 at different pH
values (Fig 5) results in efficient presentation of T-cell epitopes
in the context of MHC-II on human moDCs (Fig 6) and promotes
TH2-biased immune responses in mice (Fig 3).
In summary, our data clearly show that the pH-dependent
stability of Bet v 1 is a key factor for allergenicity and
immunogenicity in vivo and that epitope-specific T-cell activation
is highly influenced by the fold stability of the protein. Our results
also provide a mechanism for how real-life ligand binding to the
hydrophobic cavity of Bet v 1 could render the molecule highly
allergenic (ie, by inducing a change in fold stability similar to
that observed for Bet_mut4). This has direct implications for
the use of recombinant Bet v 1.0101 for allergen-specific
immunotherapy because in the absence of a ligand, the
recombinant protein might not be optimal in stimulating potent
T-cell responses. Thus in addition to increasing the understanding
of structural determinants of allergenicity, our findings have
broader implications for a rational design of hyperimmunogenic
antigens for vaccination, as well as hypoimmunogenic molecules
for use as biological agents.
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Key messages
d Fold stability is a key determinant of the sensitizing po-
tential of allergen molecules.
d Efficient TH2 cell activation requires both an increased
stability at the pH of the early endosome and efficient
degradation at a lower pH resembling the late endoso-
mal/lysosomal compartment.
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